Video

Dr Chelsee Jensen on the Solution to Stocking Multiple Biosimilars for the Same Reference Product

Author(s):

Chelsee Jensen, PharmD, pharmaceutical formulary manager at the Mayo Clinic, provides her take on why practices will have to continue to stock multiple biosimilars for the same reference product.

Chelsee Jensen, PharmD, pharmaceutical formulary manager at the Mayo Clinic, provides her take on why practices will have to continue to stock multiple biosimilars for the same reference product.

Transcript

What can practices do to help manage the possibility of having to stock and manage multiple biosimilars for the same reference product?

Jensen: Unfortunately, I do not see this going away anytime soon until we have some more of that biosimilar parity legislation or more collaboration between health systems and payers on choosing preferred products. Until then, we're going to have to stock whatever biosimilars are covered by the patient's insurance in order to prevent that patient liability.

Newsletter

Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.

Related Videos
Michael Hassett, MD, MPH, Dana-Farber Cancer Institute
Emilie Aschenbrenner, PharmD, BCOP, Froedtert Health and the Medical College of Wisconsin
Clayton Irvine, PharmD, MBA, MS
AJMC Managed Markets Network Logo
CH LogoCenter for Biosimilars Logo